Exhibiting at Middle East Poultry Expo 2025

CZ Vaccines S.A.U., based in O Porriño, Spain, is a distinguished biotechnology company specializing in the development, manufacturing, and commercialization of vaccines and biological products. A part of Zendal Group, CZ Vaccines operates at the forefront of both human and veterinary health, offering robust Contract Development and Manufacturing Organization (CDMO) services worldwide.

Core Business Areas

CZ Vaccines operates across three primary business segments:

• Human Health: Production and development of viral, bacterial, and DNA-based vaccines for various human diseases. Products include vaccines for diseases with high epidemic potential, such as OCUREV.

• Animal Health: Manufacturing of a broad spectrum of veterinary vaccines, diagnostic kits, and pharmaceutical products tailored for livestock, aquaculture, and companion animals.

• CDMO Services: Providing end-to-end services for third-party biotechnology clients, from vaccine formulation and development to full-scale GMP-certified manufacturing.

Specialisation and Core USP

CZ Vaccines is known for its cutting-edge biotechnology capabilities and its strong track record in both human and veterinary vaccine development. It is one of the few facilities in Europe capable of handling the full lifecycle of vaccine production including antigen discovery, bulk production, fill-finish, and packaging.

Their proprietary vaccine platforms, such as those used for OCUREV (COVID-19 vaccine candidate) and BLUEVAC BTV (for bluetongue virus), showcase their flexibility in both conventional and genetic vaccine technologies. They have also invested significantly in DNA vaccine development and immunotherapy solutions.

Financial Performance

As part of Zendal, a leading Spanish pharmaceutical group, CZ Vaccines contributes significantly to the group’s overall financial growth:

• Group Revenue (Zendal): Over EUR 75 million in 2023
• Annual R&D Spend (Zendal Group): EUR 10 million+
• CZ Vaccines’ Export Share: Approx. 60% of production exported internationally

Though CZ-specific financials are not separately disclosed, it remains the largest contributor within the Zendal portfolio, based on public filings and industry reports.

Shipment and Export Records

According to export analytics from trade platforms like ImportYeti and Trademo:

• Main Export Markets: Latin America, Africa, EU, and Southeast Asia
• Top Shipped Products: OCUREV, B19 CZV, and BLUEVAC veterinary vaccines
• Shipment Volume: Over 1,000 global vaccine consignments annually
• Key Clients: Ministries of Health, International NGOs, and pharmaceutical companies

Target Markets

CZ Vaccines serves a diverse client base including:

• Government and public health agencies
• Multinational pharmaceutical firms
• Agricultural cooperatives and veterinary networks
• Biotech firms seeking CDMO partnerships

Capabilities

CZ Vaccines' facility is recognized for its technical excellence and scalability. Notable features include:

• Fully integrated GMP-certified production lines
• BSL-3 laboratories for high-risk pathogen work
• Freeze-drying (lyophilization) capability
• Automated fill-finish lines for large-volume vaccine output

They also maintain a strong scientific staff and invest in continuous professional development and innovation.

Certifications and Compliance

CZ Vaccines adheres to strict international quality and safety standards, including:

• GMP Certification (EU): For both human and veterinary product lines
• ISO 13485: Medical devices quality management
• WHO PQ (Prequalification): For vaccines supplied to UN agencies
• Animal Health Certification (EMA): European Medicines Agency compliance for veterinary use

Customer Testimonials

“CZ Vaccines has demonstrated agility and scientific rigor in the rapid scale-up of critical vaccine solutions. Their team’s commitment to public health is unparalleled.” — Ministry of Health, Latin American Government

“Working with CZ Vaccines on CDMO projects has given us access to state-of-the-art technology and manufacturing expertise.” — Biotech Partner, EU

Major Achievements

• Successfully developed and produced OCUREV, a COVID-19 vaccine candidate, in collaboration with the Spanish government.
• Expanded global footprint through WHO-compliant vaccine supplies to Africa and Asia.
• Integral role in the EU-funded “BLUEVAC” project addressing bluetongue virus in livestock.
• Active participant in multiple Horizon 2020 research programs.

CZ Vaccines continues to push the boundaries of biotechnology through innovation, strategic partnerships, and a commitment to improving global health outcomes in both humans and animals.